Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2013

View Archived Issues

Stimulation of developmental pathways to reverse structural and cognitive deficits in trisomy 21

Update on phase III investigation of a novel radiotracer for the detection of oral carcinoma

Phase II results presented for blosozumab, a monoclonal antibody targeting sclerostin

PDI and Transgenomic to commercialize the CardioPredict molecular diagnostic test

Seragon Pharmaceuticals raises funds to advance pipeline of cancer therapies

AAA reaches halfway recruitment milestone in phase III Lutathera trial

Hybrigenics acquires Imaxio's genomics division

Dance Biopharm forms joint venture with Harmony Asset for inhaled insulin

Zydus and Pieris enter alliance for novel Anticalin therapeutics

Phase I trial of KEA-0447/KRP-EPA605 for treatment of overactive bladder begins

U.S. DoD and MediVector set to advance anti-influenza drug to phase III

Nosopharm secures funding from French government to support development of new antibiotic class

Yale researchers begin trial of Halozyme's recombinant hyaluronidase in artificial pancreas

New drug combination for Parkinson's disease allows lower doses with enhanced clinical effects

Highly selective DPP IV inhibitor shows outstanding results in vivo

Merck KGaA patents TANK1/2 inhibitors

Incozen and Rhizen jointly report HGF receptor inhibitors

Novel BTK inhibitors described in Takeda patent

Canadian researchers design SH2 domain variants

Rebiotix begins phase II trial in recurrent Clostridium difficile-associated diarrhea

Omeros reports additional data from phase I OMS-824 program

Relypsa reports topline data from phase IIb trial of patiromer

Misodel vaginal delivery system approved for labor induction in Europe

Phase Ia VGX-100 trial completes patient enrollment

Studies support serum biomarker test to predict optimal treatment, long-term outcome in HF patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...